The process of developing and testing newdrugs takes quite a long time, which is especially valuable in curing numerous diseases that constantly take their lives. Traditional methods require three to five years to complete the entire procedure for testing a new drug. Developers from startup AI Exscientia (UK) and pharmaceutical company Sumitomo Dainippon Pharma (Japan) plan to reduce the development and testing time for drugs to one year.
New drug DSP-1181 under developmentdesigned to cure patients suffering from obsessive-compulsive disorder (OCD), characterized by pathological fears or the development of obsessive thoughts. OCD currently affects millions of people around the world.
Oxford startup Exscientia offers foraccelerated development and testing of the drug use the special Centaur Chemist machine learning platform, which takes advantage of artificial intelligence to enable operational research.
Artificial Intelligence Centaur Chemist is capable ofstudy and analyze several million molecular combinations and identify the most effective for the treatment of OCD. The accelerated development of new drugs can provide a quick cure and lead to an economic effect of billions of dollars.